Agomab reports positive interim data in Crohn’s disease trial
Belgian biotech Agomab Therapeutics (Nasdaq: AGMB) has reported positive interim results from its Phase IIa STENOVA trial of AGMB-129, an oral gut-restricted small molecule ALK5 inhibitor in development for fibrostenosing Crohn’s disease.
The analysis includes data from 44 patients who completed 12 weeks of treatment, with the study meeting both its primary and secondary endpoints. The primary goal of the global trical is to assess the drug’s safety and tolerability, while secondary measures include pharmacokinetics and target engagement in intestinal strictures.
Following these results, Agomab has initiated an open-label extension of the study, allowing patients who completed the initial 12-week treatment to continue receiving AGMB-129 for up to 48 weeks.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze